Table 3. HGF, Eotaxin/CCL11, MCP-1/CCL2, Rantes/CCL5, EGF and MIP-1β/CCL4 comparison in the test and validation cohorts.
| RR-MS | Progressive MS | |
|---|---|---|
| Test cohort | ||
| HGF [pg/mL] | 117 (67–351)** | 406 (188–508) |
| Eotaxin/CCL11 [pg/mL] | 69 (44–99)** | 119±65 |
| MCP-1/CCL2 [pg/mL] | 325 (265–519) # | 447 (337–561) |
| Rantes/CCL5 [pg/mL] | 2,359 (1,105–6,066)*** | 7,791 (5,548–7,791) |
| EGF [pg/mL] | 55 (8–89)*** | 8 (8–8) |
| MIP-1β/CCL4 [pg/mL] | 135 (88–183)*** | 51 (37–93) |
| Validation cohort | ||
| HGF [pg/mL] | 334 (239–430)** | 536 (344–805) |
| Eotaxin/CCL11 [pg/mL] | 88 (60–122)*** | 230 (121–381) |
| MCP-1/CCL2 [pg/mL] | 357 (205–461)*** | 680 (391–1,005) |
| Rantes/CCL5 [pg/mL] | 2,641 (1,649–4,841)*** | 23,644 (4,029–23,644) |
| EGF [pg/mL] | 106 (63–155) # | 64 (46–106) |
| MIP-1β/CCL4 [pg/mL] | 131 (95–189) # | 94 (79–129) |
Mann—Whitney statistical test was used for calculation of the reported p-value between RR-MS vs Progressive MS; RR-MS = Relapsing-Remitting MS patients. Note that the Relapsing-remitting group comprises the clinical groups: RR-MS Remission, RR-MS Active, RESPONDERS, NON RESPONDERS and RELAPSES. The Progressive group comprises Secondary (SP-MS) and Primary-progressive patients.
Results are given as Median value (IQR1–3). Statistical significance is marked as:
*p<0.05;
**p<0.01;
***p<0.001.
# p = 0.06 (trend).